publication . Other literature type . Article . 2018

Permanent Chemotherapy‐Induced Alopecia in Patients with Breast Cancer: A 3‐Year Prospective Cohort Study

Hae Kwang Lee; Yeon Hee Park; Juhee Cho; Jeong Eon Lee; Danbee Kang; Danbee Kang; Young Hyuck Im; Eun Kyung Choi; Eliseo Guallar; Eliseo Guallar; ...
Open Access
  • Published: 17 Aug 2018
  • Publisher: Alphamed Press
Abstract
Chemotherapy‐induced alopecia is (CIA) considered temporary; however, some patients report persistent alopecia several years after chemotherapy. Long‐term prospective data on the incidence and impact of permanent CIA is scarce. This article reports the results of a study conducted to estimate the long‐term incidence of persistent CIA in a cohort of breast cancer patients with measurements of hair volume and density before and after chemotherapy.
Subjects
Medical Subject Headings: skin and connective tissue diseasesmacromolecular substancesmusculoskeletal diseasesintegumentary systemmusculoskeletal system
free text keywords: 3, 26, Symptom Management and Supportive Care, Chemotherapy, Alopecia, Breast neoplasm, Cohort, Cancer Research, Oncology, Regimen, medicine.medical_treatment, medicine, Hair loss, medicine.disease, Adverse effect, Internal medicine, medicine.medical_specialty, Breast cancer, Prospective cohort study, business.industry, business, Sequela
Related Organizations
Funded by
NIH| MOUSE GENETICS
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 2P30CA008748-43
  • Funding stream: NATIONAL CANCER INSTITUTE
32 references, page 1 of 3

1 Yabroff KR, Lawrence WF, Clauser S et al. Burden of illness in cancer survivors: Findings from a population‐based national sample. J Natl Cancer Instit 2004;96:1322–1330.

2 Nissen MJ, Swenson KK, Ritz LJ et al. Quality of life after breast carcinoma surgery: A comparison of three surgical procedures. Cancer 2001;91:1238–1246.11283922 [PubMed]

3 Zielinski C, Beslija S, Mrsic‐Krmpotic Z et al. Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first‐line chemotherapy in metastatic breast cancer: A Central European Cooperative Oncology Group international, multicenter, prospective, randomized phase III trial. J Clin Oncol 2005;23:1401–1408.15735116 [PubMed]

4 Kim IR, Cho JH, Choi EK et al. Perception, attitudes, preparedness and experience of chemotherapy‐induced alopecia among breast cancer patients: A qualitative study. Asian Pac J Cancer Prev 2012;13:1383–1388.22799336 [PubMed]

5 McGarvey EL, Baum LD, Pinkerton RC et al. Psychological sequelae and alopecia among women with cancer. Cancer Pract 2001;9:283–289.11879330 [OpenAIRE] [PubMed]

6 Paus R, Haslam IS, Sharov AA et al. Pathobiology of chemotherapy‐induced hair loss. Lancet Oncol 2013;14:e50–e59.23369683 [PubMed]

7 Grevelman EG, Breed WP. Prevention of chemotherapy‐induced hair loss by scalp cooling. Ann Oncol 2005;16:352–358.15642703 [PubMed]

8 Hesketh PJ, Batchelor D, Golant M et al. Chemotherapy‐induced alopecia: Psychosocial impact and therapeutic approaches. Support Care Cancer 2004;12:543–549.15221580 [PubMed]

9 Sredni B, Xu RH, Albeck M et al. The protective role of the immunomodulator AS101 against chemotherapy‐induced alopecia studies on human and animal models. Int J Cancer 1996;65:97–103.8543404 [PubMed]

10 Bleiker TO , Nicolaou N, Traulsen J et al. ‘Atrophic telogen effluvium’ from cytotoxic drugs and a randomized controlled trial to investigate the possible protective effect of pretreatment with a topical vitamin d analogue in humans. Br J Dermatol 2005;153:103–112.16029334 [PubMed]

11 Shin H, Jo SJ, Kim DH et al. Efficacy of interventions for prevention of chemotherapy‐induced alopecia: A systematic review and meta‐analysis. Int J Cancer 2015;136:E442–E454.25081068 [PubMed]

12 van den Hurk CJ, Peerbooms M, van de Poll‐Franse LV et al. Scalp cooling for hair preservation and associated characteristics in 1411 chemotherapy patients ‐ results of the Dutch Scalp Cooling Registry. Acta Oncol 2012;51:497–504.22304489 [OpenAIRE] [PubMed]

13 Komen MMC, Smorenburg CH, van den Hurk CJ et al. Factors influencing the effectiveness of scalp cooling in the prevention of chemotherapy‐induced alopecia. The Oncologist 2013;18:885–891.23650021 [OpenAIRE] [PubMed]

14 Nangia J, Wang T, Osborne C et al. Effect of a scalp cooling device on alopecia in women undergoing chemotherapy for breast cancer: The SCALP randomized clinical trial. JAMA 2017;317:596–605.28196254 [PubMed]

15 van den Hurk CJ, van den Akker‐van Marle ME, Breed WP et al. Cost‐effectiveness analysis of scalp cooling to reduce chemotherapy‐induced alopecia. Acta Oncol 2014;53:80–87.24059270 [PubMed]

32 references, page 1 of 3
Abstract
Chemotherapy‐induced alopecia is (CIA) considered temporary; however, some patients report persistent alopecia several years after chemotherapy. Long‐term prospective data on the incidence and impact of permanent CIA is scarce. This article reports the results of a study conducted to estimate the long‐term incidence of persistent CIA in a cohort of breast cancer patients with measurements of hair volume and density before and after chemotherapy.
Subjects
Medical Subject Headings: skin and connective tissue diseasesmacromolecular substancesmusculoskeletal diseasesintegumentary systemmusculoskeletal system
free text keywords: 3, 26, Symptom Management and Supportive Care, Chemotherapy, Alopecia, Breast neoplasm, Cohort, Cancer Research, Oncology, Regimen, medicine.medical_treatment, medicine, Hair loss, medicine.disease, Adverse effect, Internal medicine, medicine.medical_specialty, Breast cancer, Prospective cohort study, business.industry, business, Sequela
Related Organizations
Funded by
NIH| MOUSE GENETICS
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 2P30CA008748-43
  • Funding stream: NATIONAL CANCER INSTITUTE
32 references, page 1 of 3

1 Yabroff KR, Lawrence WF, Clauser S et al. Burden of illness in cancer survivors: Findings from a population‐based national sample. J Natl Cancer Instit 2004;96:1322–1330.

2 Nissen MJ, Swenson KK, Ritz LJ et al. Quality of life after breast carcinoma surgery: A comparison of three surgical procedures. Cancer 2001;91:1238–1246.11283922 [PubMed]

3 Zielinski C, Beslija S, Mrsic‐Krmpotic Z et al. Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first‐line chemotherapy in metastatic breast cancer: A Central European Cooperative Oncology Group international, multicenter, prospective, randomized phase III trial. J Clin Oncol 2005;23:1401–1408.15735116 [PubMed]

4 Kim IR, Cho JH, Choi EK et al. Perception, attitudes, preparedness and experience of chemotherapy‐induced alopecia among breast cancer patients: A qualitative study. Asian Pac J Cancer Prev 2012;13:1383–1388.22799336 [PubMed]

5 McGarvey EL, Baum LD, Pinkerton RC et al. Psychological sequelae and alopecia among women with cancer. Cancer Pract 2001;9:283–289.11879330 [OpenAIRE] [PubMed]

6 Paus R, Haslam IS, Sharov AA et al. Pathobiology of chemotherapy‐induced hair loss. Lancet Oncol 2013;14:e50–e59.23369683 [PubMed]

7 Grevelman EG, Breed WP. Prevention of chemotherapy‐induced hair loss by scalp cooling. Ann Oncol 2005;16:352–358.15642703 [PubMed]

8 Hesketh PJ, Batchelor D, Golant M et al. Chemotherapy‐induced alopecia: Psychosocial impact and therapeutic approaches. Support Care Cancer 2004;12:543–549.15221580 [PubMed]

9 Sredni B, Xu RH, Albeck M et al. The protective role of the immunomodulator AS101 against chemotherapy‐induced alopecia studies on human and animal models. Int J Cancer 1996;65:97–103.8543404 [PubMed]

10 Bleiker TO , Nicolaou N, Traulsen J et al. ‘Atrophic telogen effluvium’ from cytotoxic drugs and a randomized controlled trial to investigate the possible protective effect of pretreatment with a topical vitamin d analogue in humans. Br J Dermatol 2005;153:103–112.16029334 [PubMed]

11 Shin H, Jo SJ, Kim DH et al. Efficacy of interventions for prevention of chemotherapy‐induced alopecia: A systematic review and meta‐analysis. Int J Cancer 2015;136:E442–E454.25081068 [PubMed]

12 van den Hurk CJ, Peerbooms M, van de Poll‐Franse LV et al. Scalp cooling for hair preservation and associated characteristics in 1411 chemotherapy patients ‐ results of the Dutch Scalp Cooling Registry. Acta Oncol 2012;51:497–504.22304489 [OpenAIRE] [PubMed]

13 Komen MMC, Smorenburg CH, van den Hurk CJ et al. Factors influencing the effectiveness of scalp cooling in the prevention of chemotherapy‐induced alopecia. The Oncologist 2013;18:885–891.23650021 [OpenAIRE] [PubMed]

14 Nangia J, Wang T, Osborne C et al. Effect of a scalp cooling device on alopecia in women undergoing chemotherapy for breast cancer: The SCALP randomized clinical trial. JAMA 2017;317:596–605.28196254 [PubMed]

15 van den Hurk CJ, van den Akker‐van Marle ME, Breed WP et al. Cost‐effectiveness analysis of scalp cooling to reduce chemotherapy‐induced alopecia. Acta Oncol 2014;53:80–87.24059270 [PubMed]

32 references, page 1 of 3
Any information missing or wrong?Report an Issue